首页> 外文期刊>Nature reviews. Urology >Bladder cancer: Predicting response to BCG.
【24h】

Bladder cancer: Predicting response to BCG.

机译:膀胱癌:预测对BCG的反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Methylation status of a select panel of genes can predict failure of bacillus Calmette-Guerin (BCG) immunotherapy, according to research carried out by Marta Sanchez-Carbayo and colleagues at the Spanish National Cancer Research Centre in Madrid. Intravesical BCG is the treatment of choice for patients with non-muscle-invasive bladder cancer who are considered to be at high risk of recurrence and progression to muscle-invasive disease. However, about a third of recipients do not respond to BCG, and the ability to identify which patients might require more-aggressive management is a major goal of bladder cancer research today.
机译:根据马德里西班牙国家癌症研究中心的Marta Sanchez-Carbayo及其同事进行的研究,选择的一组基因的甲基化状态可以预测卡介苗-卡林芽孢杆菌(BCG)免疫疗法的失败。膀胱内BCG是非肌肉浸润性膀胱癌患者的首选治疗方法,这些患者被认为具有复发和发展为肌肉浸润性疾病的高风险。但是,约有三分之一的接受者对BCG没有反应,而确定哪些患者可能需要更积极治疗的能力是当今膀胱癌研究的主要目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号